This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Research Validates New Biomarkers For Risk Assessment Of Acute Kidney Injury

WASHINGTON, Feb. 6, 2013 /PRNewswire-USNewswire/ -- Two biomarkers used in combination can improve risk assessment of acute kidney injury (AKI), according to new research from an international multi-center study. AKI strikes up to seven percent of hospitalized patients and is associated with significant morbidity and mortality.

The results, published today in Critical Care, address one of the most costly and deadly conditions affecting critically ill hospitalized patients. The findings provide much needed insight into the most compelling biomarkers of acute kidney injury.

"If unchecked, AKI can lead to loss of kidney function in a patient, often resulting in lower quality of life or even death," said Dr. John Kellum, a critical care physician at UPMC. "The data show that two urinary biomarkers of AKI can tell a doctor if a patient is at risk of kidney injury."

The two-part study collected data on critically ill patients in North American and Europe.

In the first part of the study, led by Dr. Kianoush Kashani of Mayo Clinic, researchers performed an exhaustive evaluation of nearly 340 biomarkers to define the two best biomarkers with the highest correlation to risk of acute kidney injury. 

In the second part of the study, led by Dr. John Kellum, a critical care physician at UPMC and Lakhmir Chawla, anesthesiologist at The GW Medical Faculty Associates and associate professor of Anesthesiology & Critical Care medicine and of Medicine at The George Washington University School of Medicine & Health Sciences, researchers from 35 medical centers validated the effectiveness of the two novel biomarkers in 740 critically ill patients and compared their performance with other biomarkers, including serum creatinine.
  • The two novel biomarkers validated were Insulin-like growth factor-binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases-2 (TIMP-2), both inducers of G1 cell cycle arrest, a key mechanism implicated in AKI.
  • Together IGFBP7 and TIMP-2 demonstrated an AUC of .80 (0.76 and 0.79, respectively).
  • Together IGFBP7 and TIMP-2 were superior to all commonly used markers of AKI (p<0.002), none of which achieved an AUC > 0.72.

"The results are striking not only in terms of identifying new robust markers that have improved performance characteristics when directly compared with existing methods for assessing risk of AKI, but also in terms of bolstering understanding of the mechanism of this disease," said Dr. Chawla.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,751.39 +121.12 0.69%
S&P 500 2,108.57 +15.32 0.73%
NASDAQ 5,111.7330 +22.5270 0.44%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs